|
Synonyms: IBI 308 | IBI-308 | IBI308 | Tyvyt®
sintilimab is an approved drug (China (2018))
Compound class:
Antibody
Comment: Sintilimab (IBI 308) is a fully human IgG4 anti-programmed cell death 1 (PD-1) monoclonal antibody [5]. It acts as an immune checkpoint inhibitor and is used clinically as an immuno-oncology therapeutic.
Ligand Activity Visualisation ChartsThese are box plot that provide a unique visualisation, summarising all the activity data for a ligand taken from ChEMBL and GtoPdb across multiple targets and species. Click on a plot to see the median, interquartile range, low and high data points. A value of zero indicates that no data are available. A separate chart is created for each target, and where possible the algorithm tries to merge ChEMBL and GtoPdb targets by matching them on name and UniProt accession, for each available species. However, please note that inconsistency in naming of targets may lead to data for the same target being reported across multiple charts. ✖ |
Classification  |
|
| Compound class | Antibody |
| Approved drug? | Yes (China (2018)) |
| International Nonproprietary Names |
|
| INN number | INN |
| 10801 | sintilimab |
| Synonyms |
| IBI 308 | IBI-308 | IBI308 | Tyvyt® |
| Database Links |
|
| Specialist databases | |
| IMGT/mAb-DB | 859 |
| Other databases | |
| CAS Registry No. | 2072873-06-2 (source: WHO INN record) |
| GtoPdb PubChem SID | 485206111 |
| Search PubMed clinical trials | sintilimab |
| Search PubMed titles | sintilimab |
| Search PubMed titles/abstracts | sintilimab |
